X
NHS saved £324 million by switching to biosimilars and generics
https://pharmaphorum.com/news/nhs-saved-millions-switching-biosimilars/
biosimilar
Mylan to market Lupin’s Enbrel biosimilar outside US
Lupin’s biosimilar is under review in EU
EC to update IP rules to benefit generic exports
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Mylan to develop Botox biosimilar with Revance
Mylan takes aim at Allergan’s off-patent blockbuster
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
Big-selling Humalog facing cut price competition
Samsung Bioepis Herceptin biosimilar approved in EU
Mylan and Biocon resolve biosimilar manufacturing issues
